Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.
We investigated the effects of soluble epoxide hydrolase (sEH) inhibition on epoxyeicosatrienoic acid (EET) metabolism in intact human blood vessels, including the human saphenous vein (HSV), coronary artery (HCA), and aorta (HA). When HSV segments were perfused with 2 micromol/l 14,15-[3H]EET for 4 h, >60% of radioactivity in the perfusion medium was converted to 14,15-dihydroxyeicosatrienoic acid (DHET). Similar results were obtained with endothelium-denuded vessels. 14,15-DHET was released from both the luminal and adventitial surfaces of the HSV. When HSVs were incubated with 14,15-[3H]EET under static (no flow) conditions, formation of 14,15-DHET was detected within 15 min and was inhibited by the selective sEH inhibitors N,N'-dicyclohexyl urea and N-cyclohexyl-N'-dodecanoic acid urea (CUDA). Similarly, CUDA inhibited the conversion of 11,12-[3H]EET to 11,12-DHET by the HSV. sEH inhibition enhanced the uptake of 14,15-[3H]EET and facilitated the formation of 10,11-epoxy-16:2, a beta-oxidation product. The HCA and HA converted 14,15-[3H]EET to DHET, and this also was inhibited by CUDA. These findings in intact human blood vessels indicate that conversion to DHET is the predominant pathway for 11,12- and 14,15-EET metabolism and that sEH inhibition can modulate EET metabolism in vascular tissue.
Fang
Xiang
X
Dept. of Biochemistry, 4-403 BSB, Univ. of Iowa College of Medicine, Iowa City, IA 52242, USA. xiang-fang@uiowa.edu
Weintraub
Neal L
NL
McCaw
Ryan B
RB
Hu
Shanming
S
Harmon
Shawn D
SD
Rice
James B
JB
Hammock
Bruce D
BD
Spector
Arthur A
AA
D015126:8,11,14-Eicosatrienoic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002478:Cells, Cultured; D003510:Cyclohexanes / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D004852:Epoxy Compounds / Q000378:metabolism; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000493:pharmacokinetics*; D007850:Lauric Acids / Q000494:pharmacology; D050356:Lipid Metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism; D010084:Oxidation-Reduction; D012501:Saphenous Vein / Q000187:drug effects / Q000201:enzymology*; D012995:Solubility; D014316:Tritium; D014665:Vasodilator Agents / Q000494:pharmacology*
C482226:12-(3-cyclo-hexyl-ureido)-dodecanoic acid; C107016:14,15-dihydroxyeicosatrienoic acid; D003510:Cyclohexanes; D004852:Epoxy Compounds; D006893:Hydroxyeicosatetraenoic Acids; D007850:Lauric Acids; D014665:Vasodilator Agents; D014316:Tritium; C046782:14,15-epoxy-5,8,11-eicosatrienoic acid; D004851:Epoxide Hydrolases; D015126:8,11,14-Eicosatrienoic Acid